Vav inhibition in graft rejection

Details for Australian Patent Application No. 2004229171 (hide)

Owner Novartis AG

Inventors Forstner, Michael; Weckbecker, Gisbert; Leder, Lukas; Raulf, Friedrich; Nusslein-Hildesheim, Barbara; Klumpp, Martin

Agent Davies Collison Cave

Pub. Number AU-B-2004229171

PCT Pub. Number WO2004/091654

Priority 0315090.1 27.06.03 GB; 0308853.1 16.04.03 GB

Filing date 15 April 2004

Wipo publication date 28 October 2004

Acceptance publication date 25 October 2007

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

27 October 2005 PCT application entered the National Phase

  PCT publication WO2004/091654 Priority application(s): WO2004/091654

25 October 2007 Application Accepted

  Published as AU-B-2004229171

3 April 2008 Standard Patent Sealed

11 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004229176-Method for producing a whey protein concentrate enriched in betalactoglobulin and texture enhancer based thereupon for use in dairy products

2004229166-Device for applying active substances to surfaces onto medical implants, in particular stents